These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 17095858

  • 1. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
    Laurencet F, Ballabeni P, Rufener B, Hess U, Cerny T, Fey M, Luthi JM, Plancherel C, Zulian GB, Swiss Group for Clinical Research (SAKK).
    Acta Haematol; 2007; 117(1):40-7. PubMed ID: 17095858
    [Abstract] [Full Text] [Related]

  • 2. Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies.
    Laurencet FM, Zulian GB, Guetty-Alberto M, Iten PA, Betticher DC, Alberto P.
    Br J Cancer; 1999 Mar; 79(7-8):1215-9. PubMed ID: 10098762
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia.
    Montillo M, Tedeschi A, O'Brien S, Di Raimondo F, Lerner S, Ferrajoli A, Morra E, Keating MJ.
    Cancer; 2003 Jan 01; 97(1):114-20. PubMed ID: 12491512
    [Abstract] [Full Text] [Related]

  • 4. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
    Lambertenghi Deliliers G, Butti C, Baldini L, Ceriani A, Lombardi F, Luoni M, Montalbetti L, Pavia G, Pinotti G, Pogliani E.
    Haematologica; 1995 Jan 01; 80(4):318-24. PubMed ID: 7590500
    [Abstract] [Full Text] [Related]

  • 5. Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group.
    Robak T, Blonski JZ, Wawrzyniak E, Gora-Tybor J, Palacz A, Dmoszynska A, Konopka L, Warzocha K, Jamroziak K.
    Cancer; 2009 Jan 01; 115(1):94-100. PubMed ID: 19025975
    [Abstract] [Full Text] [Related]

  • 6. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K.
    J Cancer Res Clin Oncol; 2002 Nov 01; 128(11):603-9. PubMed ID: 12458340
    [Abstract] [Full Text] [Related]

  • 7. Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies.
    Robak T, Szmigielska-Kapłon A, Błoński JZ, Kasznicki M, Chojnowski K.
    Chemotherapy; 2005 Aug 01; 51(5):247-51. PubMed ID: 16088121
    [Abstract] [Full Text] [Related]

  • 8. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna.
    Jaksic B, Brugiatelli M, Krc I, Losonczi H, Holowiecki J, Planinc-Peraica A, Kusec R, Morabito F, Iacopino P, Lutz D.
    Cancer; 1997 Jun 01; 79(11):2107-14. PubMed ID: 9179056
    [Abstract] [Full Text] [Related]

  • 9. A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma.
    Sawka CA, Shepherd FA, Franssen E, Brandwein J, Dotten DA, Routy JP, Walker IR, St-Louis J, Taylor M, Arts K, Crump M, Foote M.
    Biotechnol Annu Rev; 2005 Jun 01; 11():381-9. PubMed ID: 16216784
    [Abstract] [Full Text] [Related]

  • 10. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
    Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B, Warzocha K, Seferynska I, Piszcz J, Calbecka M, Kostyra A, Dwilewicz-Trojaczek J, Dmoszyñska A, Zawilska K, Hellmann A, Zdunczyk A, Potoczek S, Piotrowska M, Lewandowski K, Blonski JZ.
    J Clin Oncol; 2010 Apr 10; 28(11):1863-9. PubMed ID: 20212251
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M, Clò V, Brugiatelli M, Carotenuto M, Gobbi PG, Vallisa D, Lombardo M, Avanzini P, Di Renzo N, Dini D, Baldini L, Silingardi V.
    Haematologica; 1998 Sep 10; 83(9):800-11. PubMed ID: 9825577
    [Abstract] [Full Text] [Related]

  • 12. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.
    Tulpule A, Espina BM, Berman N, Buchanan LH, Smith DL, Sherrod A, Dharmapala D, Gee C, Boswell WD, Nathwani BN, Welles L, Levine AM.
    Clin Lymphoma Myeloma; 2006 Jul 10; 7(1):59-64. PubMed ID: 16879771
    [Abstract] [Full Text] [Related]

  • 13. Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
    Robak T, Góra-Tybor J, Lech-Marańda E, Błoński JZ, Kasznicki M.
    Eur J Haematol; 2001 Mar 10; 66(3):188-94. PubMed ID: 11350487
    [Abstract] [Full Text] [Related]

  • 14. Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group.
    Kalinka-Warzocha E, Wajs J, Lech-Maranda E, Ceglarek B, Holowiecki J, Federowicz I, Walewski J, Czyz J, Robak T, Warzocha K, Polish Lymphoma Research Group.
    Cancer; 2008 Jul 15; 113(2):367-75. PubMed ID: 18470902
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.
    Robak T, Smolewski P, Cebula B, Grzybowska-Izydorczyk O, Błoński JZ.
    Eur J Haematol; 2007 Aug 15; 79(2):107-13. PubMed ID: 17635235
    [Abstract] [Full Text] [Related]

  • 18. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
    Zinzani PL, Levrero MG, Lauria F, Rondelli D, Zaja F, Russo D, Fanin R, De Rossi G, Mauro FR, Bendandi M, Gozzetti A, Dianzani F, Mandelli F, Tura S.
    Haematologica; 1994 Aug 15; 79(1):55-60. PubMed ID: 15378949
    [Abstract] [Full Text] [Related]

  • 19. Severe myelotoxicity of oral etoposide in heavily pretreated patients with non-Hodgkin's lymphoma or chronic lymphatic leukemia.
    Shaklai S, Bairey O, Blickstein D, Prokocimer M, Hadar H, Lahav M, Sulkes J, Shaklai M.
    Cancer; 1996 Jun 01; 77(11):2313-7. PubMed ID: 8635101
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.